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Abstract
Background: With the increasing interest with botulinum toxin – A (BTX-A) application in the
lower urinary tract, we investigated the BTX-A effects on the canine prostate and also in men with
bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH).
Methods: Transperineal injection into the prostate using transrectal ultrasound (TRUS) was
performed throughout the study. Saline with or without 100 U of BTX-A was injected into mongrel
dogs prostate. One or 3 months later, the prostate was harvested for morphologic and apoptotic
study. In addition, eight BPH patients refractory to α-blockers were treated with ultrasound guided
intraprostatic injection of 200 U of BTX-A.
Results: In the BTX-A treated dogs, atrophy and diffuse apoptosis was observed with H&E stain
and TUNEL stain at 1 and 3 months. Clinically, the mean prostate volume, symptom score, and
quality of life index were significantly reduced by 18.8%, 73.1%, and 61.5% respectively. Maximal
flow rate significantly increased by 72.0%.
Conclusion: Intraprostatic BTX-A injection induces prostate apotosis in dogs and relieves BOO
in humans. It is therefore a promising alternative treatment for refractory BOO due to BPH.
Background
Benign prostatic hyperplasia (BPH) is a common feature
of the aging male and is regarded as a major cause of blad-
der outlet obstruction (BOO), which results in obstructive
and irritative voiding symptoms. The bothersome urinary
symptoms decrease the quality of life of these patients [1].
Transurethral resection of prostate (TURP) has been con-
sidered as a gold standard for the treatment of sympto-
matic BPH. However, there have been concerns about the
safety of TURP, with long-term morbidity including retro-
grade ejaculation, bladder neck contracture, and impo-
tence [2-4]. Thus, there has been much interest in the
development of alternative treatments. However, one fea-
ture of any of the minimally invasive techniques in clini-
cal use to date is that they are permanent. Some men are
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simply not ready or willing to undergo an irreversible pro-
cedure in order to treat their symptomatic BPH.
Botulinum toxin A (BTX-A) has been shown to block the
release of neurotransmitters such as acetylcholine at the
neuromuscular junction as well as in autonomic neurons
[5-7]. BTX-A has been successfully used to treat various
conditions including blepharospasm, strabismus, focal
dystonias, and achalasia [7]. Injection of BTX-A into the
urethra or bladder is an effective treatment for various
types of lower urinary tract dysfunction for 6 months or
longer [7-9]. Furthermore, previous studies in the rats
have shown that intraurethral injection of BTX-A has sig-
nificant inhibitory effects on urethral norepinephrine
release [10] and intraprostatic injection of BTX-A induces
selective denervation and subsequent atrophy of the
glands [11]. Recent clinical studies have shown promising
results after injection of BTX-A into lateral lobes of pros-
tate for relieving voiding dysfunction due to BPH [12-14].
However, the histological change of prostatic tissue and
mechanisms after BTX-A injection was not clear. The dog
is one of a few animals that can develop BPH spontane-
ously and is frequently used as an animal model for
human prostatic hyperplasia [15,16]. Therefore, the
present study investigated morphologic and apoptotic
change in the canine prostate after BTX-A injection. We
also reported 8 cases of symptomatic BPH patients treated
with BTX-A.
Methods
Animal study
The animal study was conducted at veterinary hospital,
National Pingtung University, with the approval of the
institutional review board. Eight mature male mongrel
dogs, weighing 13 to 17 kg., were used in this study. All
animals were put on the lithotomy position and received
perioperative antibiotics and intravenous sedation with
pentobarbital. One hundred units of botulinum toxin A
(BTX-A, Botox®, Allergan, Irvine CA) were dissolved in 4
ml of 0.9% saline solution. Each lobe of the prostate
received transperineal injection of 2 ml of BTX-A with
one-needle pass under TRUS guidance (Fig. 1) [16,17].
The control animals received the same procedures with
injection of normal saline.
One or three months after BTX-A or normal saline injec-
tion (N = 2, in each group), the prostate was harvested for
histological examination. The prostatic tissues were
embedded in paraffin blocks after formalin fixation. Con-
secutive sections were taken for morphologic examination
with hematoxylin and eosin stain and for study of apop-
tosis with TUNEL stain (terminal deoxynucleotidyl-medi-
ated deoxyuridine triphosphate nick end labeling stain)
[18] using a commercially available kit (Detection Kit
POD, Boehringer Mannhein, Mannhein, Germany).
Apoptotic nuclei were identified by detected fluorescence.
Human study
The effects on the human prostate and lower urinary tract
symptoms were evaluated on 8 men with symptomatic
BPH who had large prostate volume (mean 61.6 ml) and
inadequate responses or intolerable side effects to α-
blockers (Table 1). The study was approved by the institu-
tional review board of Chang Gung Memorial Hospital
Kaohsiung and informed consent was obtained. Eight
men, mean age 71.1 ± 1.9 years, were treated. All patients
had a prostate volume of greater than 40 ml and a peak
urine flow rate less than 12 ml/s. All men had a benign
digital rectal prostate exam and did not suspect clinical
malignancy. Patient 3 had PSA value at 9 ng/ml but
rejected biopsy. Patient 4 and 5 had been experiencing
chronic urinary retention for more than 1 month and
Diffusion of hyperechoic BTX-A over the canine prostate immediate after BTX-A injection Figure 1
Diffusion of hyperechoic BTX-A over the canine prostate immediate after BTX-A injection. A. Transverse view. B. Longitudinal 
view.BMC Urology 2006, 6:12 http://www.biomedcentral.com/1471-2490/6/12
Page 3 of 6
(page number not for citation purposes)
were treated with an indwelling Foley catheter. All
patients received perioperative antibiotics with cefazolin
1 g (i.v.) and intravenous sedation with propofol 50 mg
in the lithotomy position. Transperineal injection was
done under TRUS guidance (Fig. 2) [17]. As previous
study described, each lobe of the prostate received 100 U
of BTX-A (Botox®, Allergan) dissolved in 4 ml of normal
saline [13]. Two injections of equal volume (2 ml) were
given in each lobe. The total dose of BTX-A was 200 U for
each patient. Urethral catheter drainage was not per-
formed postoperatively, except in two patients with
chronic indwelling urethral catheters. These two men with
urinary retention were able to urinate spontaneously 1
week post BTX-A injection. Patient 4 who was lack of pre-
injection PSA data and was found with high PSA after
removal of Foley catheter received biopsy and proved ade-
nocarcinoma 3 months after injection. He received brach-
ytherapy and was followed-up at our out patient clinic.
All men were evaluated pre and postoperatively for Inter-
national Prostate Symptom Score (IPSS, 0–35, mild 0–7,
moderate 8–18, severe ≥ 19), quality of life indices (QOL,
0–6, indicating increasing severity of symptoms and low
quality of life) [19], peak urinary flow rates, post-void
residual volume detected by ultrasound, and prostate vol-
ume by TRUS (0.52 × Length × Height × Width). Results
were evaluated one month after the procedure. Quantita-
tive data are expressed throughout this paper as means
plus or minus standard error. Statistical analyses were per-
formed using Student's t test for paired data with p < 0.05
considered significant.
Results
Animal study
None of the dogs suffered any complications including
infection, incontinence, urinary retention, stones, and
change in ambulation or weight loss. The average prostate
volume was not significantly changed after saline or BTX-
A injection (from 11.8 ± 0.9 cc to 12.5 ± 1.1 cc and 11.0 ±
A. Confirmation of needle (black arrow) within the human prostate, longitudinal view Figure 2
A. Confirmation of needle (black arrow) within the human prostate, longitudinal view. B. Diffusion of hyperechoic BTX-A 
(black arrow) over the prostate immediate post injection.
Table 1: Patient profiles and results after botulinum toxin-A treatment.
Patient Age (yr) Prostate 
volume (ml) 
Pre/Post
PSA (ng/ml) 
Pre/Post
IPSS Pre/Post QOL index 
Pre/Post
Peak Flow 
(ml/s) Pre/
Post
Residual urine 
(ml) Pre/Post
Follow-up 
(month)
1 75 45.0/40.6 4.1/1.6 16/2 3/1 6/11 73/20 8
2 60 54.3/40.7 4.1/3.2 22/15 3/2 9.8/13 138/20 6
3 77 116.0/85.0 9.0/6.6 18/13 4/2 12/14 18/15 6
4 75 51.8/36.4 -/20.7 26/2 5/1 0/12 500/24 4
5 73 76.2/61.4 -/5.2; 4.4 25/5 5/2 0/12 500/40 4
6 70 46.3/39.3 3.6/- 11/1 3/1 12/15 72/17 4
7 72 61.8/54.9 3.3/3.5 19/2 4/2 11/14 100/48 3
8 67 41.3/41.0 2.0/2.4 15/1 4/1 9/12 20/12 3
IPSS- international prostate symptom score.
QOL- quality of life.
-: lack of data.BMC Urology 2006, 6:12 http://www.biomedcentral.com/1471-2490/6/12
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0.5 cc to 10.1 ± 0.4 cc, respectively). However, gross exam-
ination of the prostate revealed smaller in size and less
indurated after BTX-A injection than the control (Fig. 3).
The H&E stained sections of the prostate from the control
animals of the 1 and 3 months groups revealed hypertro-
phied glands (Fig. 4A). However, the H&E stained sec-
tions of the BTX-A treated animals from the 1 and 3
month post BTX-A treated groups revealed a degeneration
of the prostate glands with similar results in both groups
(Fig 4C).
The TUNEL staining of sections of control animals (1 and
3 month groups) revealed only a small amount of apop-
tosis (Fig. 4B). The TUNEL stained sections of tissue of
BTX-A treated animals revealed fluorescence in the nuclei
throughout the evaluated tissue, but fluorescence was pre-
dominantly seen in the nuclei of the glands (Fig. 4D). This
significant glandular apoptosis was seen at both 1 and 3
month after intraprostatic BTX-A injection.
The proportion of TUNEL positive nuclei per 500 nuclei
was quantified at ×400 magnification using a 10 × 10 grid
in the eyepiece in 4 fields. The mean apoptotic cells in the
BTX-A treated group and control group were 187.5 ± 20.4
and 6.5 ± 2.1, respectively (p < 0.05).
Human study
The follow-up period ranged from 3 to 8 months, mean
4.8 ± 0.6 months. No stress incontinence, retrograde ejac-
ulation, erectile dysfunction, or systemic side effects were
observed. Most patients reported improvement starting
from 3 to 7 days post BTX-A treatment, reaching maximal
effect in about 1 month, and maintaining effects as long
as eight months.
At one month follow-up, the prostate volume, mean
symptom score and quality of life index were significantly
reduced by 18.8% (from 61.6 ± 8.7 to 50.0 ± 5.9 ml, p <
0.05), 73.1% (from 19.0 ± 1.8 to 5.1 ± 2.0, p < 0.05) and
61.5% (from 3.9 ± 0.3 to 1.5 ± 0.2, p < 0.05) respectively.
The maximal flow rate was increased by 72.0% (from 7.5
± 1.8 to 12.9 ± 0.5 ml/sec, p < 0.05). The residual urine
was decreased by 86.2% (from 177.6 ± 71.7 to 24.5 ± 4.5
ml, p = 0.064). At three month follow-up, the effects were
maintained and the prostate volume, mean symptom
score, quality of life index, maximal flow rate, and resid-
ual urine were 49.5 ± 5.9 ml, 4.0 ± 0.9, 1.6 ± 0.3, 13.0 ±
0.5 ml/sec, and 22.1 ± 3.0 ml, respectively.
Discussion
Although the etiology of BPH remains unknown, it has
been suggested that BPH has two components: a static
component that is related to prostatic enlargement and a
dynamic component that reflects contraction of smooth
muscle within the gland [1,12]. The static component is
under parasympathetic control and regulated by andro-
gen, while the stromal smooth muscle is sympathetically
influenced [20,21]. Thus, drugs that relax smooth muscle
within the prostate, such as α-adrenergic receptor block-
Coronal section of canine prostate one month after BTX-A or saline injection Figure 3
Coronal section of canine prostate one month after BTX-A or saline injection. Smaller in size and less indurations after BTX-A 
injection (B) than the control (A).BMC Urology 2006, 6:12 http://www.biomedcentral.com/1471-2490/6/12
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ers, and drugs that shrink the volume, such as 5 α reduct-
ase inhibitors, are used for the treatment of BPH.
Recent evidence suggests that BPH could be originated
from neural dysregulation of the prostate and alterations
in local neuropeptides [20]. The prostatic neuroendocrine
peptides may regulate the synthesis of prostatic secretory
product, growth, and function [20,21]. Thus, BTX-A
which has a cholinergic receptor predilection in its action
on nerve terminals as well as inhibition of release of
noradrenalin might regulate the neural control of prostate
and relieve the symptoms of benign prostatic obstruction.
There are some differences between the canine and
human prostate, nevertheless, experimental findings on
the canine prostate can be regarded as valuable informa-
tion. Previous studies have used the canine mode to eluci-
date the effects of orchiectomy and androgen on the
prostate [15,22]. In the canine model, we used BTX-A 100
U for prostate injection, which dose might be about 2
times of the dose used in human (100 U for 15 kg in
canine/200 U for 60 kg in human). However, the compo-
nent of human prostate is different from the canine pros-
tate. Species differences might have different responses to
BTX-A treatment [23], therefore, the selected dose of BTX-
A 100 U for the canine model cannot be completely inter-
preted to the human dose. Our present results suggest that
injection of BTX-A into the canine prostate induced
marked atrophy and diffuse apoptosis of prostate glands.
The effect persisted for at least 3 months without any
notable side effects. Doggweiler suggested that denerva-
tion can alter growth-factor expression in the prostate and
resulted in programmed cell death [11]. Kyprianou dem-
onstrated that the suppression of sympathetic tone on the
prostate induced prostate apoptosis [24]. Expression of
specific prostate apoptosis related genes, such as bcl2 and
transforming growth factor-β has been implicated in the
pathogenesis of BPH [24]. Thus, apoptotic changes in the
prostate after BTX-A treatment are likely to be related with
reduced neurotrophic influence on the gland. Therefore,
the induction of apoptosis may emerge as an attractive tar-
get for the management of BPH. As BPH might arise from
neural dysregulation, BTX-A could potentially affect these
neural mechanisms. Further study with staining of various
neuropeptide markers in the dog prostate is undergoing
for future report.
Although one of our patients did not reveal volume
shrinkage, all of the 8 patients had improved in maximal
flow rate, residual urine, IPSS score and quality of life
indices, and had no side effects after BTX-A injection. The
pathological features of BPH are heterogenous and
include varying abnormalities of epithelium, smooth
muscle and fibrous stroma. The relative proportion of epi-
thelium and stroma is from 1:2 to 1:5 [24]. It is possible
that the predominant component of the BPH nodule may
Photomicrographs and terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining of  prostate sections after saline (A,B) and BTX-A (C,D) injection at 1 month Figure 4
Photomicrographs and terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining of 
prostate sections after saline (A,B) and BTX-A (C,D) injection at 1 month. Significant glandular proliferation with papillary 
infolding in the lumen was seen in the control canine (A). Atrophy change of glandular component with flattening of the lining 
epithelium was seen in the BTX-A treated canine (C). Very few apoptotic nuclei are recognizable in the control animal (B). 
Strong fluorescence of apoptotic nuclei was seen in the BTX-A treated animal at 1 month. A, C magnification × 40; B, D mag-
nification × 100.BMC Urology 2006, 6:12 http://www.biomedcentral.com/1471-2490/6/12
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determines the response to specific therapy, for example,
smooth muscle predominant nodules would respond to
α-blockers and epithelial nodules to androgen-depriva-
tion therapy [1,24]. The possibility of BTX-A effects on the
dynamic component of BPH might explain the patient
without volume shrinkage, but improved in lower urinary
symptoms. Taken together, BTX-A might reduce the
benign prostatic obstruction no matter what the detrusor
contractility is.
The effects of denervation provided by the BTX-A will
wear off, as new axons re-sprout in approximately 6
months [7]. Phelan et al reported that BTX-A effects on
sphincter injection have prolonged subjective clinical effi-
cacy beyond 6 months [8]. The beneficial results of the
present study were evident within 1 month, and they con-
tinued throughout the follow-up period. The duration of
BTX-A effects might depend on the different characteristic
of targeted tissue, therapeutic dose, and intervals. Patients
will determine if and when subsequent injections are nec-
essary. Since the application of BTX-A on the treatment of
lower urinary dysfunction is currently off-level use in Tai-
wan, it was necessary to be approved by the institutional
review board for the human use and animal study. In sup-
port of evidence based medicine practices, caution should
be applied until larger randomized clinical studies are
completed that will guide physicians in making decisions
about the use of botulinum toxin in the prostate.
Conclusion
In conclusion, our preliminary results suggest that BTX-A
induces prostate atrophy and apoptosis in the canine and
improves lower urinary tract symptoms in men with lower
urinary tract symptoms due to benign prostatic hyperpla-
sia. Intraprostate BTX-A injection may be a promising,
reversible and alternative treatment for refractory BPH.
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